IGL's Q4FY24 SA EBITDA/PAT of Rs5.2bn/Rs3.8bn came at a $17 \% / 13 \%$ miss to our estimates, mainly due to lower realization affecting gross margins and higher opex. Volumes were in-line, at 8.7 mmscmd , up $6 \%$ YoY and $\mathbf{3 \%}$ QoQ. EBITDA/scm at Rs6.6 missed our estimate by $17 \%$, on $11 \%$ higher unit opex. Mgmt. guided to 4-5\%/10-15\% YoY vol. growth for Delhi/other GAs, with FY25 vol. guidance at 9.5 mmscmd . DTC targets $\mathbf{1 0 0 \%}$ conversion of buses to EVs by CY25, but dumpers, inter-state buses and LNG trucks could support new GA volumes. IPNG should also grow rapidly. EBITDA/scm stands at Rs7-8.5, while capex would be Rs17-18bn p.a. We raise FY25-26E earnings by 6-8\% each, on slightly better vol.-margin profile but retain REDUCE due to a hazy outlook. We raise our DCF-based Mar-25E rolled over TP by 3\% to Rs440/sh.

| Indraprastha Gas: Financial Snapshot (Standalone) |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24 | FY25E | FY26E |
| Revenue | 77,100 | 141,326 | 140,000 | 159,769 | 177,812 |
| EBITDA | 18,811 | 20,255 | 23,669 | 27,038 | 30,008 |
| Adj. PAT | 12,896 | 14,450 | 17,481 | 19,395 | 21,340 |
| Adj. EPS (Rs) | 18.4 | 20.6 | 25.0 | 27.7 | 30.5 |
| EBITDA margin (\%) | 24.4 | 14.3 | 16.9 | 16.9 | 16.9 |
| EBITDA growth (\%) | 26.8 | 7.7 | 16.9 | 14.2 | 11.0 |
| Adj. EPS growth (\%) | 30.8 | 9.9 | 21.0 | 10.9 | 10.0 |
| RoE (\%) | 19.6 | 20.6 | 22.4 | 21.0 | 20.0 |
| RoIC (\%) | 45.8 | 47.3 | 44.2 | 37.7 | 35.7 |
| P/E (x) | 24.5 | 21.9 | 18.1 | 16.3 | 14.8 |
| EV/EBITDA (x) | 15.2 | 14.4 | 12.1 | 10.3 | 8.9 |
| P/B (x) | 4.6 | 4.5 | 3.7 | 3.2 | 2.8 |
| FCFF yield (\%) | 2.0 | 3.8 | 1.2 | 3.5 | 4.6 |

Source: Company, Emkay Research

## Result Highlights

Q4FY24 SA EBITDA/PAT rose 13\%/16\% YoY and fell 6\%/2\% QoQ. CNG volume grew 5\% YoY and was flat QoQ, coming in at 580 mmscm . PNG was up $11 \% \mathrm{YoY} / 8 \% \mathrm{QoQ}$, with I/C up $12 \% / 9 \%$ and DPNG increasing $17 \% / 15 \%$. Gross margin rose $2 \%$ QoQ to Rs13.1/scm, on lower unit gas cost. Unit opex rose $14 \% \mathrm{YoY} / 15 \%$ QoQ (11\% above est), on one-time employee incentives and given that the entire CSR expenses were booked in Q4. Other income was up 54\% YoY/79\% QoQ at Rs1.1bn (at a $70 \%$ beat). D/A rose $9 \%$ QoQ to Rs1.1bn, whereas ETR was slightly higher at $26.2 \%$. Share of profit from CUGL-MNGL was Rs815mn in Q4FY24, up 20\% YoY/down 5\% QoQ. IGL's FY24 SA Revenue/EBITDA/PAT stood at Rs140.0/23.8/17.5bn, down 1\%/up 17\%/up 21\% YoY, led by $4 \%$ YoY growth in total vol. to 8.4 mmscmd , besides the $12 \%$ rise in EBITDA/scm to Rs7.7. Board declared final dividend of Rs5/sh, implying 36\% payout for FY24.

## Management KTAs

DTC volume de-grew as CNG buses were retired and replaced by EVs. 1,200 buses are already gone, whereas $\sim 1,500$ would be withdrawn in next $2-3$ years (DTC targets $100 \%$ shift by CY25). IGL targets dumpers (as a segment) and interstate buses (in discussion with UP/Uttarakhand/Rajasthan for a 200/200/20 bus pilot). It aims to clock 9.5 mmscmd total volume in FY25 on average (1mmscmd growth YoY) with CNG sales in the 8 new GAs (ex-Delhi-Noida-Ghaziabad) and IPNG being focus areas. Expects Delhi to grow 4$5 \%$, and other GAs 10-15\%. EBITDA/scm guidance is Rs7.0-8.5. FY24 capex was Rs12.7bn; FY25 capex target is Rs17-18bn mostly on core areas, but Rs3-4bn would be on LNG retail \& CBG. IGL plans opening 10 CBG plants with Rs2-3bn capex and producing 20mt/day/plant, totaling $\sim 0.2 \mathrm{mmscmd}$. In LNG, 1 station was commissioned in Ajmer and 5-6 additions are planned for this year. IGL has signed MoU with Concor.

## Valuation

We value IGL on DCF-SoTP basis. Our SOTP-DCF-based Mar-25E TP of Rs440/share implies $12.6 \times$ Mar-26E consolidated target P/E. Key risks: Adverse pricing, margin, and currency scenarios; high gas prices; open access; rate of EV adoption; project delays.
Target Price - 12M Mar-25

Change in TP (\%) 3.4
Current Reco. REDUCE
Previous Reco. REDUCE
Upside/(Downside) (\%)
(2.5)

CMP (08-May-24) (Rs) 451.2

| Stock Data | Ticker |
| :--- | ---: |
| 52-week High (Rs) | 516 |
| 52-week Low (Rs) | 376 |
| Shares outstanding (mn) | 700.0 |
| Market-cap (Rs bn) | 316 |
| Market-cap (USD mn) | 3,782 |
| Net-debt, FY25E (Rs mn) | $-37,220$ |
| ADTV-3M (mn shares) | 3 |
| ADTV-3M (Rs mn) | $1,237.6$ |
| ADTV-3M (USD mn) | 14.8 |
| Free float (\%) | 50.0 |
| Nifty-50 | 22,303 |
| INR/USD | 83.5 |
| Shareholding, Mar-24 |  |
| Promoters (\%) | 45.0 |
| FPIs/MFs (\%) | $16.8 / 24.2$ |


| Price Performance |  |  |  |
| :--- | ---: | ---: | ---: |
| (\%) | $\mathbf{1 M}$ | $\mathbf{3 M}$ | $\mathbf{1 2 M}$ |
| Absolute | $(5.1)$ | 2.6 | $(7.6)$ |
| Rel. to Nifty | $(3.5)$ | $(0.1)$ | $(24.3)$ |



## Sabri Hazarika

sabri.hazarika@emkayglobal.com
+91 2266121282

## Harsh Maru

harsh.maru@emkayglobal.com
+912266121336

## Arya Patel

arya.patel@emkayglobal.com
+91 2266121285

[^0]Exhibit 1: Actuals vs. Estimates (Q4FY24)

| Rs mn | Actual | Estimates (Emkay) | $\begin{array}{r} \text { Consensus } \\ \text { Estimates } \\ \text { (Bloomberg) } \end{array}$ | Variation |  | Comments |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Emkay | Consensus |  |
| Total Revenue | 35,968 | 36,495 | 35,599 | -1\% | 1\% | Lower realizations |
| Adjusted EBITDA | 5,225 | 6,276 | 6,070 | -17\% | -14\% | Higher opex |
| EBITDA Margin | 14.5\% | 17.2\% | 17.1\% | -267bps | -252bps |  |
| Adjusted Net Profit | 3,828 | 4,393 | 4,282 | -13\% | -11\% | Higher other income |

Source: Company, Emkay Research

Exhibit 2: Standalone Quarterly Summary

| (Rs mn) | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | YoY | QoQ | FY23 | FY24 | YoY |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| CNG Sales | 30,348 | 28,730 | 29,413 | 29,986 | 29,766 | -2\% | -1\% | 117,880 | 117,895 | 0\% |
| Less Excise | 3,745 | 3,548 | 3,640 | 3,758 | 3,676 | -2\% | -2\% | 14,572 | 14,623 | 0\% |
| PNG Sales | 10,217 | 8,888 | 8,812 | 9,276 | 9,878 | -3\% | 6\% | 38,098 | 36,855 | -3\% |
| Net Revenues | 36,820 | 34,070 | 34,585 | 35,504 | 35,968 | -2\% | 1\% | 141,407 | 140,127 | -1\% |
| Dec./(Inc.) in Stock In Trade | (16) | 17 | (5) | (17) | (1) |  |  | (49) | (6) |  |
| Raw Material Cost | 27,941 | 23,324 | 23,808 | 25,476 | 25,529 | -9\% | 0\% | 104,409 | 98,137 | -6\% |
| Total COGS | 27,925 | 23,341 | 23,803 | 25,459 | 25,528 | -9\% | 0\% | 104,360 | 98,131 | -6\% |
| Gross Profit | 8,895 | 10,729 | 10,782 | 10,045 | 10,440 | 17\% | 4\% | 37,046 | 41,996 | 13\% |
| Employee Cost | 467 | 508 | 516 | 583 | 660 | 41\% | 13\% | 1,882 | 2,266 | 20\% |
| Other Expenses | 3,820 | 3,797 | 3,697 | 3,881 | 4,555 | 19\% | 17\% | 14,821 | 15,930 | 7\% |
| Total OPEX | 4,286 | 4,306 | 4,213 | 4,464 | 5,214 | 22\% | 17\% | 16,703 | 18,196 | 9\% |
| Total Expenditure | 32,212 | 27,646 | 28,016 | 29,923 | 30,742 | -5\% | 3\% | 121,063 | 116,327 | -4\% |
| EBITDA | 4,608 | 6,424 | 6,569 | 5,582 | 5,225 | 13\% | -6\% | 20,343 | 23,800 | 17\% |
| Depreciation | 938 | 989 | 1,022 | 1,018 | 1,108 | 18\% | 9\% | 3,634 | 4,138 | 14\% |
| EBIT | 3,671 | 5,435 | 5,547 | 4,563 | 4,118 | 12\% | -10\% | 16,710 | 19,663 | 18\% |
| Interest | 26 | 24 | 25 | 18 | 26 | 0\% | 44\% | 106 | 92 | -14\% |
| Other Income | 709 | 457 | 1,340 | 610 | 1,094 | 54\% | 79\% | 2,674 | 3,500 | 31\% |
| PBT before exceptional | 4,354 | 5,867 | 6,862 | 5,155 | 5,187 | 19\% | 1\% | 19,277 | 23,072 | 20\% |
| Exceptional items | - | - | - | - | - |  |  | - | - |  |
| PBT | 4,354 | 5,867 | 6,862 | 5,155 | 5,187 | 19\% | 1\% | 19,277 | 23,072 | 20\% |
| Current tax | 1,056 | 1,398 | 1,380 | 1,049 | 1,227 | 16\% | 17\% | 4,397 | 5,054 | 15\% |
| Deferred tax | 0 | 86 | 134 | 186 | 132 |  | -29\% | 430 | 537 |  |
| Total tax | 1,057 | 1,483 | 1,514 | 1,235 | 1,359 | 29\% | 10\% | 4,827 | 5,591 | 16\% |
| Reported PAT | 3,298 | 4,384 | 5,348 | 3,921 | 3,828 | 16\% | -2\% | 14,450 | 17,481 | 21\% |
| Rep. EPS (Rs) | 4.7 | 6.3 | 7.6 | 5.6 | 5.5 | 16\% | -2\% | 20.6 | 25.0 | 21\% |
| Adjusted PAT | 3,298 | 4,384 | 5,348 | 3,921 | 3,828 | 16\% | -2\% | 14,450 | 17,481 | 21\% |
| Adj. EPS (Rs) | 4.7 | 6.3 | 7.6 | 5.6 | 5.5 | 16\% | -2\% | 20.6 | 25.0 | 21\% |
| CUGL/MNGL Gross PAT | 1,355 | 1,672 | 1,803 | 1,715 | 1,630 | 20\% | -5\% | 5,073 | 6,820 | 34\% |
| CUGL/MNGL EPS Contri (Rs) | 1.0 | 1.2 | 1.3 | 1.2 | 1.2 | 20\% | -5\% | 3.6 | 4.9 | 34\% |
| Consol. Adj. EPS ex Div. Adj. (Rs) | 5.7 | 7.5 | 8.9 | 6.8 | 6.6 | 17\% | -3\% | 24.3 | 29.8 | 23\% |
| Shares O/S (mn) | 700 | 700 | 700 | 700 | 700 |  |  | 700 | 700 |  |
| EBITDA margin | 13\% | 19\% | 19\% | 16\% | 15\% |  |  | 14\% | 17\% |  |
| Standalone Rep. NPM | 9\% | 13\% | 15\% | 11\% | 11\% |  |  | 10\% | 12\% |  |
| Effective tax rate | 24\% | 25\% | 22\% | 24\% | 26\% |  |  | 25\% | 24\% |  |
| Total Sales (mmscmd) | 8.3 | 8.2 | 8.3 | 8.5 | 8.7 | 6\% | 3\% | 8.1 | 8.4 | 4\% |
| CNG Volumes ( mmscm ) | 550 | 561 | 575 | 582 | 580 | 5\% | 0\% | 2,209 | 2,298 | 4\% |
| PNG Volumes (mmscm) | 193 | 185 | 189 | 198 | 214 | 11\% | 8\% | 743 | 786 | 6\% |
| Domestic | 56 | 52 | 53 | 57 | 65 | 17\% | 15\% | 197 | 227 | 15\% |
| Industrial+Commercial | 92 | 87 | 90 | 95 | 104 | 12\% | 9\% | 364 | 376 | 3\% |
| 3rd party Trading | 45 | 45 | 46 | 46 | 45 | 2\% | -1\% | 182 | 182 | 0\% |
| Gross Margin (Rs/scm) | 12.0 | 14.4 | 14.1 | 12.9 | 13.1 | 10\% | 2\% | 12.6 | 13.6 | 8\% |
| Adj. EBITDA/scm (Rs) | 6.2 | 8.6 | 8.6 | 7.2 | 6.6 | 6\% | -8\% | 6.9 | 7.7 | 12\% |
| CNG Real (Rs/kg) | 75.9 | 71.3 | 70.9 | 71.7 | 71.4 | -6\% | 0\% | 73.2 | 71.3 | -3\% |
| PNG Real (Rs/scm) | 53.0 | 48.1 | 46.6 | 46.8 | 46.1 | -13\% | -2\% | 51.2 | 46.9 | -8\% |
| Average Real (Rs/scm) | 49.6 | 45.7 | 45.3 | 45.5 | 45.3 | -9\% | 0\% | 47.9 | 45.4 | -5\% |
| Capex | 4,300 | 2,600 | 2,160 | 3,200 | 4,040 | -6\% | 26\% | 11,900 | 12,000 | 1\% |

[^1]Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 3: Change in assumptions

|  | FY25E |  |  | FY26E |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Previous | Revised | Variance | Previous | Revised | Variance |
| EBITDA/scm (Rs) | 7.5 | 7.8 | 4\% | 7.5 | 7.9 | 5\% |
| Sales Volumes (mmscmd) | 9.4 | 9.5 | 2\% | 10.1 | 10.5 | 3\% |
| Growth | 10.4\% | 13.0\% | 260bps | 7.9\% | 9.9\% | 200bps |

Source: Company, Emkay Research

## Exhibit 4: Change in estimates

| (Rs mn) | FY25E |  |  | FY26E |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
|  | Previous | Revised | Variance | Previous | Revised |
| Revenue | 159,053 | 159,769 | $0 \%$ | 173,784 | 177,812 |
| EBITDA | 25,680 | 27,038 | $5 \%$ | 27,743 | 30,008 |
| EBITDA Margins | $16.1 \%$ | $16.9 \%$ | 78 bps | $16.0 \%$ | $16.9 \%$ |
| PAT | 18,277 | 19,395 | $6 \%$ | 19,702 | 21,340 |
| EPS (Rs) | 26.1 | 27.7 | $6 \%$ | 28.1 | 30.5 |

Source: Company, Emkay Research

## Concall Key Takeaways

- Indraprastha Gas's (IGL's) Q4FY24 volume growth in Delhi was flat YoY; Noida/Greater Noida-Ghaziabad volume grew $10 \%$ and new areas are seeing a wide volume range, with $149 \%$ in one GA, $123 \%$ in Kanpur, $60 \%$ in Meerut, and $15 \%$ YoY in 'others' on a low-variable base. $90 \%$ of volumes are from the three old (previous) GAs (NCR ex Gurgaon). IPNG volumes were flat last year due to alternate fuel pricing, but showed impressive growth in Q4. CNG sales came in at $5 \mathrm{mn} \mathrm{kg} /$ day in total, with $3.5 \mathrm{mn} \mathrm{kg} /$ day from Delhi itself.

■ DTC volumes de-grew, as CNG buses were retired and replaced by EVs. 1,200 buses are already gone, with $1,700-1,800$ (also stated that $1,300-1,400$ will be withdrawn later) would be retired in the next $2-3$ years (DTC targets $100 \%$ shift by CY25). 30 CNG stations have been affected, with volumes down from $0.35 \mathrm{mn} \mathrm{kg} /$ day to $0.185 \mathrm{mn} \mathrm{kg} / \mathrm{day}$. DIMTS will take some more time. Life of DTC buses has ended (10-15 years), so they cannot be redeployed elsewhere.

- Monthly conversion run-rate in FY24 was $10 \%$ higher YoY at 15,500 (14,000 in FY23), with CVs (L\&MH) seeing traction (up from 1,800 earlier to 2,400). Month-wise in Apr/Mar/Feb/Jan '24, total conversion was $15,500 / 15,700 / 15,800 / 19,000$, respectively, while for Dec-23 and prior was 13-15,000.
- For the taxi segment, conversion was $2,100 / 2,000 / 1,950 / 2,300$ and 1,700 , hence EV policy impact is yet to be seen. Expect EV policy impact to take some time. Auto OEMs are coming with new variants, and CNG vehicle numbers are increasing day by day. CNG penetration is $27-28 \%$. Net vehicle additions are lower than gross additions, as it is a 20 -year-old industry with retirements (no data available).
- Targets dumpers as a segment, especially in Banda+ GA, with a pilot being sanctioned and to be done in the next 1 month using 2-3 vehicles to demonstrate benefits. Dumpers have $1-1.5$-year payback period for Rs0.1-0.12mn conversion cost. Dumper operators seem to be positive, but have yet to demonstrate favorable economics and set up infra/stations.
- Wrt interstate buses, company is in discussions with UP for a 200 bus pilot, with Uttarakhand for 200, and with Rajasthan for a 20 bus pilot. Uttarakhand has already bought 160 buses, with 200 more in process; it has also reduced taxes \& prices on CNG. These buses consume $80-100 \mathrm{~kg}$ CNG per day as they run for $300-400 \mathrm{~km}$ with a $3-4 \mathrm{~km} / \mathrm{kg}$ mileage.
- LPG-propane competition exists, but CPNG has pricing advantage, though IPNG is a bulk category with discounts by propane players; hence, IGL needs to strategize for competing with this which it is working on. There is a $5-7 \%$ advantage vs propane currently.
- GA-wise volume breakup is 0.35 mmscmd for Rewari and 0.11 mmscmd for Muzaffarnagar; hence these areas have seen significant volume growth with a critical mass and, going
ahead, should grow $15 \%$ annually. Ajmer is growing at 50-60\%, though volume size is lower at 0.08 mmscmd . IGL is putting up online stations which should boost volumes.

■ Banda+ has 4 stations, which are daughter boosters, but the steel trunkline is being constructed. Marketing is under way there as well as elsewhere. Dumper conversion is expected in 2 years. All GAs are EBITDA-positive except Banda, and opex/scm will fall as volumes grow; in 2 years, this should also turn positive. Gross margin is nevertheless good.

- IGL aims to clock 9.5 mmscmd total volumes in FY25 on an average ( 1 mmscmd growth YoY) with CNG sales in the 8 new GAs (ex Delhi-Noida-Ghaziabad) and IPNG being focus areas. Expect DPNG to grow $\sim 15 \%$ YoY with $>0.3 \mathrm{mn}$ connections to be added annually, with focused areas in Delhi itself. Delhi should see growth of 4-5\% while others would grow 10$15 \%$. DTC impact on CNG would be mitigated by other avenues. LNG will also add up.
- Gas sourcing mix across segments is $72 \%$ domestic and $28 \%$ RLNG. Gap between domestic gas and RLNG has reduced to 10-12\%. Against the Rs27-28/scm domestic landed cost, some RLNG at Rs31-32/scm is seen. Company has medium- and long-term contracts. It does not expect domestic gas allocation to go up; it should remain range-bound. Nondomestic gas breakup is $60 \%$ Henry Hub linked and $40 \%$ Brent-JKM linked. 0.38 mmscmd is HP-HT gas tied up.
- EBITDA/scm guidance is Rs7.0-8.5, though Company has already achieved Rs7.67 in FY24 and same can be considered as an indicator for the future. IGL would balance profit with volume growth, and look to diversify. Trade margins have been settled with OMCs for all GAs except Delhi and Mumbai, where some disputes still exist. Trade margin is Rs5-5.5/kg in Delhi and somewhat lower in other GAs.
- Capex in FY24 was Rs12.7bn. Company added 90 new CNG stations in FY24, with 30-40 upgrades also done (126 in total). Total number of stations stood at 882 as of FY24-end, with sale/compression capacity at $4.5 / 11 \mathrm{mn} \mathrm{kg} / \mathrm{day}$. DPNG add was 0.33 mn , with while steel/MDPE add at $187 / 3,000 \mathrm{~km}$ in FY24.

■ Going ahead, capex would be Rs17-18bn in FY25, mostly on core areas, but Rs3-4bn would be on LNG retail and CBG. 40\% of capex would be in older areas (Delhi-NCR). MWP target needs to be met and IGL already ahead in the game. It is planning to diversify to renewable energy/solar power which would reduce power cost. Company plans to utilize idle capacity of small-scale LNG in GAs. It is also doing hydrogen pilot studies with IIT Delhi and Jodhpur wrt the gas network and transport segments. Action would be taken based on this, with FY25 being the target year.

■ IGL is planning 10 CBG plants with Rs2-3bn capex, and each will have production of $20 \mathrm{mt} /$ day, thereby totaling to $\sim 0.2 \mathrm{mmscmd}$. This entails nil transport cost and CBG is cheaper than APM, with Gujarat VAT also to be avoided. In LNG, 1 station has been commissioned in Ajmer and 5-6 are planned to be added this year. IGL has signed an MoU with Concor and 1 station each will be set up in its depots in Noida and Bangalore captively. Concor will increase the number of LNG trucks gradually vs 100 now.

- LNG usage is $70-80 \mathrm{~kg}$ per day per truck. Currently, LNG is being sold at Rs10-12 /unit lower than diesel, i.e. diesel is at Rs96-97/Itr, whereas LNG is Rs82-83/kg in Ajmer, providing arbitrage opportunities to users. Margins are similar to CNG's and Company expects to maintain the same. LNG and CBG would also scale up and improve profitability. Company is in discussions with a few LNG operators.

■ Q4FY24 opex was affected by CSR expense, which was booked at one go versus quarterly pro-rata earlier. Employee cost was higher due to incentives given on IGL completing 25 years. Legal fees were also higher due to ongoing court cases (Gurgaon, PNGRB, etc), and there was IndAS lease impact too, as tenure was reduced in some items and booked above EBITDA vs D/A earlier.

| Exhibit 6: DCF-based valuation (Mar-25E) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| DCF Assumptions |  | Mar 2026E (Rs mn) | Core IGL | CUGL 50\% | MNGL 50\% | Consol |
| Risk Free Rate | 7.0\% | NPV Of FCF | 142,967 | 4,757 | 25,848 |  |
| Risk Premium | 5.3\% | Terminal Value | 275,324 | 5,863 | 41,969 |  |
| Beta | 0.9 | PV Of TV | 74,768 | 1,592 | 11,397 |  |
| Cost Of Equity | 11.5\% | Total Value | 217,735 | 6,349 | 37,245 |  |
| Cost Of Debt | 8.0\% | Less: Adj. Net Debt (Mar-25E) | -43,858 | -1,557 | -1,110 |  |
| Post Tax Cost Of Debt | 6.0\% | Equity Value | 261,593 | 7,906 | 38,355 | 307,854 |
| Average Debt:Equity Ratio | 0\% | No. Of Shares O/S (mn) | 700 | 700 | 700 | 700 |
| WACC | 11.5\% | Target Price (Rs/sh) | 374 | 11 | 55 | 440 |
| Terminal Growth Rate |  |  |  |  |  |  |
| IGL | 0.0\% |  |  |  |  |  |
| CUGL | 0.0\% |  |  |  |  |  |
| MNGL | 0.0\% |  |  |  |  |  |

Source: Company, Emkay Research

| Exhibit 7: PER-based valuation (Mar-26E EPS) |  |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Rs | FY21 | FY22 | FY23 | FY24 | FY25E | FY26E |
| IGL's Core EPS | 14.4 | 18.4 | 20.6 | 25.0 | 27.7 | 30.5 |
| Less: CU/MNGL Div. Inc. | 0.4 | 0.7 | 0.8 | 1.1 | 1.2 | 1.3 |
| IGL Adjusted EPS | $\mathbf{1 4 . 0}$ | $\mathbf{1 7 . 8}$ | $\mathbf{1 9 . 8}$ | $\mathbf{2 3 . 9}$ | $\mathbf{2 6 . 5}$ | $\mathbf{2 9 . 2}$ |
| CUGL/MNGL EPS Contri. | 1.8 | 3.2 | 3.6 | 4.9 | 5.4 | 5.8 |
| Consol. EPS | $\mathbf{1 5 . 8}$ | $\mathbf{2 1 . 0}$ | $\mathbf{2 3 . 5}$ | $\mathbf{2 8 . 8}$ | $\mathbf{3 1 . 9}$ | $\mathbf{3 5 . 0}$ |
| Implied Target Multiple (x) |  |  |  |  |  | 12.6 |
| DCF Target Price (Rs/sh) |  |  |  |  |  | $\mathbf{4 4 0}$ |

Source: Company, Emkay Research

[^2]
## Indraprastha Gas: Standalone Financials and Valuations

| Profit \& Loss |  |  |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24 | FY25E | FY26E |
| Revenue | $\mathbf{7 7 , 1 0 0}$ | $\mathbf{1 4 1 , 3 2 6}$ | $\mathbf{1 4 0 , 0 0 0}$ | $\mathbf{1 5 9 , 7 6 9}$ | $\mathbf{1 7 7 , 8 1 2}$ |
| Revenue growth (\%) | 56.0 | 83.3 | $(0.9)$ | 14.1 | 11.3 |
| EBITDA | $\mathbf{1 8 , 8 1 1}$ | $\mathbf{2 0 , 2 5 5}$ | $\mathbf{2 3 , 6 6 9}$ | $\mathbf{2 7 , 0 3 8}$ | $\mathbf{3 0 , 0 0 8}$ |
| EBITDA growth (\%) | 26.8 | 7.7 | 16.9 | 14.2 | 11.0 |
| Depreciation \& Amortization | 3,171 | 3,634 | 4,138 | 5,013 | 5,761 |
| EBIT | $\mathbf{1 5 , 6 4 1}$ | $\mathbf{1 6 , 6 2 1}$ | $\mathbf{1 9 , 5 3 1}$ | $\mathbf{2 2 , 0 2 4}$ | $\mathbf{2 4 , 2 4 7}$ |
| EBIT growth (\%) | 31.1 | 6.3 | 17.5 | 12.8 | 10.1 |
| Other operating income | 0 | 0 | 0 | 0 | 0 |
| Other income | 1,810 | 2,762 | 3,632 | 4,012 | 4,390 |
| Financial expense | 132 | 106 | 92 | 107 | 108 |
| PBT | $\mathbf{1 7 , 3 1 9}$ | $\mathbf{1 9 , 2 7 7}$ | $\mathbf{2 3 , 0 7 2}$ | $\mathbf{2 5 , 9 2 9}$ | $\mathbf{2 8 , 5 3 0}$ |
| Extraordinary items | 340 | 0 | 0 | 0 | 0 |
| Taxes | 4,509 | 4,827 | 5,591 | 6,534 | 7,189 |
| Minority interest | 0 | 0 | 0 | 0 | 0 |
| Income from JV/Associates | 0 | 0 | 0 | 0 | 0 |
| Reported PAT | $\mathbf{1 3 , 1 5 0}$ | $\mathbf{1 4 , 4 5 0}$ | $\mathbf{1 7 , 4 8 1}$ | $\mathbf{1 9 , 3 9 5}$ | $\mathbf{2 1 , 3 4 0}$ |
| PAT growth (\%) | 30.8 | 9.9 | 21.0 | 10.9 | 10.0 |
| Adjusted PAT | $\mathbf{1 2 , 8 9 6}$ | $\mathbf{1 4 , 4 5 0}$ | $\mathbf{1 7 , 4 8 1}$ | $\mathbf{1 9 , 3 9 5}$ | $\mathbf{2 1 , 3 4 0}$ |
| Diluted EPS (Rs) | $\mathbf{1 8 . 4}$ | $\mathbf{2 0 . 6}$ | $\mathbf{2 5 . 0}$ | $\mathbf{2 7 . 7}$ | $\mathbf{3 0 . 5}$ |
| Diluted EPS growth (\%) | 30.8 | 9.9 | 21.0 | 10.9 | 10.0 |
| DPS (Rs) | $\mathbf{5 . 5}$ | $\mathbf{1 3 . 0}$ | $\mathbf{9 . 0}$ | $\mathbf{8 . 3}$ | $\mathbf{9 . 1}$ |
| Dividend payout (\%) | $\mathbf{2 9 . 3}$ | $\mathbf{6 3 . 0}$ | $\mathbf{3 6 . 0}$ | $\mathbf{3 0 . 0}$ | $\mathbf{3 0 . 0}$ |
| EBITDA margin (\%) | 24.4 | 14.3 | 16.9 | 16.9 | 16.9 |
| EBIT margin (\%) | 20.3 | 11.8 | 14.0 | 13.8 | 13.6 |
| Effective tax rate (\%) | 27.5 | 25.0 | 24.2 | 25.2 | 25.2 |
| NOPLAT (pre-IndAS) | $\mathbf{1 1 , 3 4 0}$ | $\mathbf{1 2 , 4 5 9}$ | $\mathbf{1 4 , 7 9 8}$ | $\mathbf{1 6 , 4 7 4}$ | $\mathbf{1 8 , 1 3 7}$ |
| Shares outstanding (mn) | 700.0 | 700.0 | 700.0 | 700.0 | 700.0 |

Source: Company, Emkay Research

| Cash flows |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24 | FY25E | FY26E |
| PBT | 17,319 | 19,277 | 23,072 | 25,929 | 28,530 |
| Others (non-cash items) | 1,302 | 1,393 | 984 | 1,109 | 1,479 |
| Taxes paid | $(3,759)$ | $(4,833)$ | $(4,871)$ | $(6,028)$ | $(6,683)$ |
| Change in NWC | 3,777 | 6,469 | $(3,828)$ | 1,666 | 1,612 |
| Operating cash flow | 18,979 | 22,306 | 15,357 | 22,676 | 24,937 |
| Capital expenditure | $(13,370)$ | $(11,221)$ | $(12,021)$ | $(13,021)$ | $(12,522)$ |
| Acquisition of business | 0 | 0 | 0 | 0 | 0 |
| Interest \& dividend income | 798 | 1,618 | 2,096 | 4,012 | 4,390 |
| Investing cash flow | $(13,401)$ | $(1,015)$ | $(11,849)$ | $(9,186)$ | $(8,311)$ |
| Equity raised/(repaid) | 0 | - | 0 | 0 | 0 |
| Debt raised/(repaid) | (765) | (638) | (540) | 0 | 0 |
| Payment of lease liabilities | (765) | (765) | (765) | (765) | (765) |
| Interest paid | 0 | 0 | 0 | (107) | (108) |
| Dividend paid (incl tax) | $(2,519)$ | $(12,948)$ | $(2,797)$ | $(5,818)$ | $(6,402)$ |
| Others | 0 | 0 | 0 | 0 | 0 |
| Financing cash flow | $(3,285)$ | $(13,586)$ | $(3,337)$ | $(5,925)$ | $(6,510)$ |
| Net chg in Cash | 2,294 | 7,705 | 171 | 7,565 | 10,116 |
| OCF | 18,979 | 22,306 | 15,357 | 22,676 | 24,937 |
| Adj. OCF (w/o NWC chg.) | 15,202 | 15,837 | 19,185 | 21,010 | 23,325 |
| FCFF | 5,610 | 11,085 | 3,335 | 9,654 | 12,416 |
| FCFE | 6,275 | 12,597 | 5,339 | 13,559 | 16,698 |
| OCF/EBITDA (\%) | 100.9 | 110.1 | 64.9 | 83.9 | 83.1 |
| FCFE/PAT (\%) | 47.7 | 87.2 | 30.5 | 69.9 | 78.2 |
| FCFF/ NOPLAT (\%) | 49.5 | 89.0 | 22.5 | 58.6 | 68.5 |

Source: Company, Emkay Research

| Balance Sheet |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E Mar (Rs mn) | FY22 | FY23 | FY24 | FY25E | FY26E |
| Share capital | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 |
| Reserves \& Surplus | 67,962 | 69,466 | 84,117 | 97,694 | 112,632 |
| Net worth | 69,362 | 70,866 | 85,517 | 99,094 | 114,032 |
| Minority interests | 0 | 0 | 0 | 0 | 0 |
| Deferred tax liability (net) | 2,737 | 3,168 | 3,695 | 4,202 | 4,709 |
| Total debt | 1,076 | 828 | 812 | 820 | 828 |
| Total liabilities \& equity | 73,175 | 74,861 | 90,025 | 104,116 | 119,569 |
| Net tangible fixed assets | 47,694 | 55,147 | 63,728 | 73,111 | 81,107 |
| Net intangible assets | 121 | 121 | 121 | 121 | 121 |
| Net ROU assets | 2,203 | 2,067 | 2,139 | 2,161 | 2,182 |
| Capital WIP | 13,786 | 14,337 | 13,964 | 12,568 | 11,311 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Investments [JV/Associates] | 2,980 | 7,891 | 5,896 | 5,896 | 5,896 |
| Cash \& equivalents | 30,793 | 25,513 | 30,299 | 38,040 | 48,336 |
| Current assets (ex-cash) | 6,947 | 12,710 | 15,057 | 16,683 | 18,181 |
| Current Liab. \& Prov. | 31,349 | 42,925 | 41,181 | 44,465 | 47,567 |
| NWC (ex-cash) | $(24,402)$ | $(30,215)$ | $(26,124)$ | $(27,782)$ | $(29,385)$ |
| Total assets | 73,175 | 74,861 | 90,025 | 104,116 | 119,569 |
| Net debt | $(29,717)$ | $(24,685)$ | $(29,487)$ | $(37,220)$ | $(47,508)$ |
| Capital employed | 73,175 | 74,861 | 90,025 | 104,116 | 119,569 |
| Invested capital | 25,616 | 27,120 | 39,865 | 47,612 | 54,025 |
| BVPS (Rs) | 99.1 | 101.2 | 122.2 | 141.6 | 162.9 |
| Net Debt/Equity (x) | (0.4) | (0.3) | (0.3) | (0.4) | (0.4) |
| Net Debt/EBITDA ( x ) | (1.6) | (1.2) | (1.2) | (1.4) | (1.6) |
| Interest coverage ( x ) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| RoCE (\%) | 25.8 | 26.2 | 28.1 | 26.8 | 25.6 |

Source: Company, Emkay Research

| Valuations and key Ratios |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Y/E Mar | FY22 | FY23 | FY24 | FY25E | FY26E |
| P/E (x) | 24.5 | 21.9 | 18.1 | 16.3 | 14.8 |
| P/CE(x) | 20.1 | 17.5 | 14.6 | 12.9 | 11.7 |
| P/B ( x ) | 4.6 | 4.5 | 3.7 | 3.2 | 2.8 |
| EV/Sales ( x ) | 3.7 | 2.1 | 2.1 | 1.8 | 1.5 |
| EV/EBITDA ( x ) | 15.2 | 14.4 | 12.1 | 10.3 | 8.9 |
| EV/EBIT(x) | 18.3 | 17.5 | 14.7 | 12.7 | 11.1 |
| EV/IC (x) | 11.2 | 10.7 | 7.2 | 5.9 | 5.0 |
| FCFF yield (\%) | 2.0 | 3.8 | 1.2 | 3.5 | 4.6 |
| FCFE yield (\%) | 2.0 | 4.0 | 1.7 | 4.3 | 5.3 |
| Dividend yield (\%) | 1.2 | 2.9 | 2.0 | 1.8 | 2.0 |
| DuPont-RoE split |  |  |  |  |  |
| Net profit margin (\%) | 16.3 | 10.2 | 12.5 | 12.1 | 12.0 |
| Total asset turnover (x) | 1.1 | 1.9 | 1.7 | 1.6 | 1.6 |
| Assets/Equity (x) | 1.1 | 1.1 | 1.1 | 1.1 | 1.0 |
| RoE (\%) | 19.6 | 20.6 | 22.4 | 21.0 | 20.0 |
| DuPont-RoIC |  |  |  |  |  |
| NOPLAT margin (\%) | 14.7 | 8.8 | 10.6 | 10.3 | 10.2 |
| IC turnover (x) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| RoIC (\%) | 45.8 | 47.3 | 44.2 | 37.7 | 35.7 |
| Operating metrics |  |  |  |  |  |
| Core NWC days | (22.4) | (2.6) | (3.0) | (3.2) | (3.1) |
| Total NWC days | (22.4) | (2.6) | (3.0) | (3.2) | (3.1) |
| Fixed asset turnover | 1.3 | 2.1 | 1.7 | 1.7 | 1.6 |
| Opex-to-revenue (\%) | 18.6 | 11.8 | 13.0 | 12.6 | 12.7 |

[^3]
## RECOMMENDATION HISTORY - DETAILS

| Date | Closing <br> Price (INR) | TP (INR) | Rating | Analyst |
| :--- | ---: | ---: | :--- | :--- |
| 07-Mar-24 | 430 | 425 | Reduce | Sabri Hazarika |
| 30-Jan-24 | 426 | 450 | Add | Sabri Hazarika |
| 30-Nov-23 | 389 | 445 | Add | Sabri Hazarika |
| 02-Nov-23 | 390 | 445 | Hold | Sabri Hazarika |
| 20-Oct-23 | 403 | 500 | Hold | Sabri Hazarika |
| 26-Jul-23 | 470 | 500 | Hold | Sabri Hazarika |
| 23-Jul-23 | 494 | 500 | Hold | Sabri Hazarika |
| 16-May-23 | 485 | 500 | Hold | Sabri Hazarika |
| 30-Mar-23 | 438 | 485 | Buy | Sabri Hazarika |
| 28-Jan-23 | 418 | 485 | Buy | Sabri Hazarika |
| 01-Dec-22 | 434 | 450 | Buy | Sabri Hazarika |
| 24-Oct-22 | 383 | 450 | Buy | Sabri Hazarika |
| 02-Oct-22 | 397 | 465 | Buy | Sabri Hazarika |
| 27-Sep-22 | 423 | 465 | Buy | Sabri Hazarika |
| 10-Aug-22 | 380 | 450 | Buy | Sabri Hazarika |
| 19-May-22 | 366 | 450 | Buy | Sabri Hazarika |
| 23-Nov-21 | 494 | 645 | Buy | Sabri Hazarika |
| 10-Nov-21 | 491 | 645 | Buy | Sabri Hazarika |
| 29-Sep-21 | 519 | 635 | Buy | Sabri Hazarika |
| 14-Aug-21 | 535 | 635 | Buy | Sabri Hazarika |
| 26-Jul-21 | 547 | 610 | Buy | Sabri Hazarika |
| 25-Jun-21 | 513 | 610 | Buy | Sabri Hazarika |
| 23-Jun-21 | 519 | 610 | Buy | Sabri Hazarika |
| 18-Jun-21 | 532 | 610 | Buy | Sabri Hazarika |
| 29-May-21 | 514 | 610 | Buy | Sabri Hazarika |
| Souce:Comany |  |  |  |  |

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity \& Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.
EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.
EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.
This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.
EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.
This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.
Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities $15 a 6$ chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.
This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

## RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests 2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.
${ }^{1}$ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.
${ }^{2}$ Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of May 9, 2024
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report Disclosure of previous investment recommendation produced:
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of May 9, 2024
5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of $1 \%$ or more securities of the subject company at the end of the month immediately preceding the May 9, 2024
6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

| Ratings | Expected Return within the next 12-18 months. |
| :--- | :--- |
| BUY | $>15 \%$ upside |
| ADD | $5-15 \%$ upside |
| REDUCE | $5 \%$ upside to $15 \%$ downside |
| SELL | $<15 \%$ downside |

## Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899
7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India
Tel: +91 2266121212 Fax: +91 2266121299 Web: www.emkayglobal.com

## OTHER DISCLAIMERS AND DISCLOSURES:

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.
Research Analyst or his/her associate/relative's may have financial interest in the subject company.
EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of $1 \%$ or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of $1 \%$ or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.
EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

SESHADRI


[^0]:    This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 06/27/2024 05:44 PM
    Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions Refer to Important Disclosures at the end of this report
    on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or
    Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

[^1]:    Source: Company, Emkay Research

[^2]:    Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

[^3]:    Source: Company, Emkay Research

